Satellos Bioscience (MSLE) Change in Working Capital (2025 - 2026)

Satellos Bioscience's (MSLE) quarterly Change in Working Capital came in at -$9.6 million in Q1 2026, down 230.12% year-on-year from $7.4 million in Q1 2025, and down 230.12% on a QoQ basis from $7.4 million in Q1 2025.

Satellos Bioscience (MSLE) Change in Working Capital (2025 - 2026) Analysis & Trends

Satellos Bioscience (MSLE) has 2 years of Change in Working Capital data on file, last reported at -$9.6 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Working Capital (Qtr)
1 Oculis Holding AG 65,719.23 Bn 65,718.94 Bn - -
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 471.85 Bn 467.06 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 122.29 Bn 115.04 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 70.04 Bn 61.28 Bn 3.31 Bn -
7 Belite Bio 62.06 Bn 62.06 Bn - -
8 Argenx Se 55.78 Bn 50.60 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.47 Bn 34.47 Bn 959.66 Mn -
10 Satellos Bioscience 177.16 Mn 177.16 Mn - -9.59 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -9.59 Mn
Mar 31, 2026 -9.59 Mn
Mar 31, 2025 7.37 Mn
Mar 31, 2025 7.37 Mn